-
Chen R, Zhang D, Mao Y, Zhu J, Ming H, Wen J, Ma J, Cao Q, Lin H, Tang Q, Liang J, Feng Z, 2012: A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo[J]. Mol Cancer Ther, 11, 594-603. doi: 10.1158/1535-7163.MCT-11-0725
-
Cho HI, Kim UH, Shin AR, Won JN, Lee HJ, Sohn HJ, Kim TG, 2018: A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy[J]. Br J Cancer, 118, 534-545. doi: 10.1038/bjc.2017.475
-
Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS, 1993: Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells[J]. J Exp Med, 177, 339-349. doi: 10.1084/jem.177.2.339
-
Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, Hammerschmidt W, 2003: Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus[J]. Cancer Res, 63, 2982-2989. doi: 10.1097/00002820-200306000-00012
-
Fennewald S, van Santen V, Kieff E, 1984: Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein[J]. J Virol, 51, 411-419.
-
Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, Pich D, Hammerschmidt W, 1997: Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule[J]. EMBO J, 16, 6131-6140. doi: 10.1093/emboj/16.20.6131
-
Hislop AD, Taylor GS, Sauce D, Rickinson AB, 2007: Cellular responses to viral infection in humans: lessons from Epstein-Barr virus[J]. Annu Rev Immunol, 25, 587-617. doi: 10.1146/annurev.immunol.25.022106.141553
-
Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G, 1996: Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein[J]. Proc Natl Acad Sci U S A, 93, 11085-11090. doi: 10.1073/pnas.93.20.11085
-
Kutz H, Reisbach G, Schultheiss U, Kieser A, 2008: The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus[J]. Virology, 371, 246-256. doi: 10.1016/j.virol.2007.09.044
-
Lin X, Gudgeon NH, Hui EP, Jia H, Qun X, Taylor GS, Barnardo MC, Lin CK, Rickinson AB, Chan AT, 2008: CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients[J]. Cancer Immunol Immunother, 57, 963-975. doi: 10.1007/s00262-007-0427-8
-
Lu ZX, Ma XQ, Yang LF, Wang ZL, Zeng L, Li ZJ, Li XN, Tang M, Yi W, Gong JP, Sun LQ, Cao Y, 2008: DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma[J]. Cancer Lett, 265, 226-238. doi: 10.1016/j.canlet.2008.02.019
-
Omar N, Lim TS, 2018: Construction of naive and immune human Fab phage-display library[J]. Methods Mol Biol, 1701, 25-44. doi: 10.1007/978-1-4939-7447-4
-
Pope JH, Horne MK, Scott W, 1968: Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus[J]. Int J Cancer, 3, 857-866. doi: 10.1002/(ISSN)1097-0215
-
Williams H, Crawford DH, 2006: Epstein-Barr virus: the impact of scientific advances on clinical practice[J]. Blood, 107, 862-869.
-
Xiao X, Ho M, Zhu Z, Pastan I, Dimitrov DS, 2009: Identification and characterization of fully human anti-CD22 monoclonal antibodies[J]. MAbs, 1, 297-303. doi: 10.4161/mabs.1.3.8113
-
Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, Liu Q, Wang L, Feng Y, Wang Y, Zheng BJ, Yuen KY, Jiang S, Dimitrov DS, 2014: Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies[J]. J Virol, 88, 7796-7805. doi: 10.1128/JVI.00912-14
-
Young LS, Rickinson AB, 2004: Epstein-Barr virus: 40 years on[J]. Nat Rev Cancer, 4, 757-768. doi: 10.1038/nrc1452